Abstract
Patients with chronic heart failure (HF) and patients with cirrhosis have worse outcomes when they also have hyponatremia, yet few effective, easily implemented management strategies for hyponatremia exist. Tolvaptan, a vasopressin V2-receptor antagonist, has shown promise for managing volume overload in hospitalized HF patients and for increasing their serum sodium levels without adverse effects on blood pressure, electrolyte levels, or renal function (for phase-2 trial results, see Journal …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
